Recombinant PE Anti-UBE2I / UBC9 antibody [EP2938Y] (ab209920)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- PE Rabbit monoclonal [EP2938Y] to UBE2I / UBC9
- Suitable for: Flow Cyt (Intra)
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
Related conjugates and formulations
Overview
-
Product name
PE Anti-UBE2I / UBC9 antibody [EP2938Y]
See all UBE2I / UBC9 primary antibodies -
Description
PE Rabbit monoclonal [EP2938Y] to UBE2I / UBC9 -
Host species
Rabbit -
Conjugation
PE. Ex: 488nm, Em: 575nm -
Tested applications
Suitable for: Flow Cyt (Intra)more details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Flow Cyt (intra): HepG2 cells.
-
General notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at 4°C (stable for up to 12 months). Upon delivery aliquot. Store at +4°C. Do Not Freeze. Store In the Dark. -
Storage buffer
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP2938Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab209920 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/500.
|
Notes |
---|
Flow Cyt (Intra)
1/500. |
Target
-
Function
Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. -
Tissue specificity
Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus. -
Pathway
Protein modification; protein sumoylation. -
Sequence similarities
Belongs to the ubiquitin-conjugating enzyme family. -
Cellular localization
Nucleus. Cytoplasm. Mainly nuclear. In spermatocytes, localizes in synaptonemal complexes. Recruited by BCL11A into the nuclear body. - Information by UniProt
-
Database links
- Entrez Gene: 7329 Human
- Entrez Gene: 100044900 Mouse
- Entrez Gene: 22196 Mouse
- Entrez Gene: 25573 Rat
- Omim: 601661 Human
- SwissProt: P63279 Human
- SwissProt: P63280 Mouse
- SwissProt: P63281 Rat
see all -
Alternative names
- C358B7.1 antibody
- p18 antibody
- SUMO 1 protein ligase antibody
see all
Images
-
Overlay histogram showing HepG2 cells stained with ab209920 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Triton X-100 for 15 min at 22°C. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab209920, 1/500 dilution) for 30 min at 22°C.
Isotype control antibody (black line) was rabbit IgG (monoclonal) Phycoerythrin (ab209478) used at the same concentration and conditions as the primary antibody. Unlabelled sample (blue line) was also used as a control.
Acquisition of >5,000 events were collected using a 50 mW Yellow/Green laser (561nm) and 586/15 bandpass filter.
This antibody gave a positive signal in HepG2 cells fixed with 4% formaldehyde (10 min)/permeabilized with 0.1% PBS-Triton X-100 at 22°C for 15 min used under the same conditions.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab209920 has not yet been referenced specifically in any publications.